FEDERAL COURT OF AUSTRALIA
Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth (No 2) [2010] FCA 1212
Citation: Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth (No 2) [2010] FCA 1212 Parties: SIGMA PHARMACEUTICALS (AUSTRALIA) PTY LTD v WYETH and WYETH AUSTRALIA PTY LIMITED
ALPHAPHARM PTY LIMITED v WYETH and WYETH AUSTRALIA PTY LIMITED
GENERIC HEALTH PTY LTD v WYETH and WYETH AUSTRALIA PTY LIMITED
File numbers: VID 195 of 2009
NSD 596 of 2009
NSD 1124 of 2009Judge: JAGOT J Date of judgment: 8 November 2010 Catchwords: PATENTS – patent held valid and infringed – relief pending appeal – stay of injunction – whether undertakings appropriate
COSTS – proceedings heard together – whether usual orders as to costs should be made – whether apportionment of costs appropriate
PRACTICE AND PROCEDURE – confidentiality of part of reasons for judgment
Legislation: Federal Court of Australia Act 1976 (Cth)
Patents Act 1990 (Cth)Cases cited: Advanced Building Systems v Ramset Fasteners (Aust) Pty Ltd (1997) 145 ALR 121
Aiden Shipping Ltd v Interbulk Ltd [1986] AC 965
Alexander v Cambridge Credit Corp Ltd (1985) 2 NSWLR 685
Alphapharm Pty Limited v Wyeth (2009) 82 IPR 71; [2009] FCA 945
Australian Broadcasting Corporation v Lenah Game Meats Pty Limited (2001) 208 CLR 199; [2001] HCA 63
Caboolture Park Shopping Centre Pty Ltd (In liquidation) v White Industries (Qld) Pty Ltd (1993) 45 FCR 224
Federal Commissioner of Taxation v Myer Emporium Ltd (No 1) (1986) 160 CLR 220
Kirin-Amgen Inc v Transkaryotic Therapies Inc (No 3) [2005] FSR 41
Henderson v Amadio Pty Ltd (1996) 136 ALR 593
Hollier v Australian Maritime Safety Authority [1998] FCA 428
Knight v FP Special Assets Limited (1992) 174 CLR 178
Minnesota Mining & Manufacturing Company v Johnson & Johnson Limited [1976] RPC 671
Red Bull Australia Pty Limited v Sydneywide Distributors Pty Limited [2001] FCA 1750
Sigma Pharmaceuticals (Australia) Pty Ltd (ACN 004 118 594) v Wyeth (2009) IPR 339; [2009] FCA 595
Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth [2010] FCA 1211
Stirling Harbour Services Pty Ltd v Bunbury Port Authority (No 2) [2000] FCA 87
Trade Practices Commission v Arnotts Ltd (1990) 93 ALR 638
Virgin Atlantic v Premium Aircraft [2009] EWCA Civ 1513
Westaflex (Aust) Pty Ltd v Wood (1990) 18 IPR 168Date of hearing: 28 October 2010 Date of last submissions: 3 November 2010 Place: Sydney Division: GENERAL DIVISION Category: Catchwords Number of paragraphs: 47 Counsel for the Applicant / Cross-Respondent in VID 195 of 2009: Mr D Shavin QC and Ms HMJ Rofe Solicitor for the Applicant / Cross-Respondent in VID 195 of 2009: Griffith Hack Lawyers Counsel for the Applicant / Cross-Respondent in NSD 596 of 2009: Mr SCG Burley SC and Mr PW Flynn Solicitor for the Applicant / Cross-Respondent in NSD 596 of 2009: Mallesons Stephen Jaques Counsel for the Applicant / Cross-Respondent in NSD 1124 of 2009: Ms AH Bowne SC Solicitor for the Applicant / Cross-Respondent in NSD 1124 of 2009: Middletons
Keep reading for free
Create a free CaseChat account to read Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth (No 2) and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2010] FCA 1212
- Decision Date
CaseChat Overview and Summary
The court found that Wyeth was successful in defending the validity of the patent against all the applicants. Consequently, the applicants' claims for invalidity and revocation of the patent were dismissed. The court also found that the applicants had threatened to infringe the patent by planning to market their own generic versions of the extended-release venlafaxine hydrochloride product. The court granted Wyeth an injunction to prevent such infringement, and ordered the destruction of any products already in the possession of the applicants.
The applicants argued for a stay of the final injunction and for interlocutory orders to protect their interests pending their appeals. They contended that without such orders, they would face significant market disadvantages if Wyeth were to enter the market with its own generic product or if the undertakings Wyeth had previously given in relation to interlocutory orders were not extended to cover the final orders. The court considered the principles governing stays and interlocutory orders pending appeal, including the nature and complexity of the proceedings, the risk of harm to the applicants if the orders were not granted, and the willingness of the parties to provide undertakings as to damages. However, the court concluded that the proposed orders would result in manifest unfairness to Wyeth and would grant the applicants benefits they could not obtain through the proceedings or the appeals. Therefore, the court denied the stay and interlocutory orders.
Regarding costs, while the applicants proposed a single costs order with an apportionment between them, the court decided to make the usual order as to costs in each proceeding due to the opposition of Generic Health to the proposed apportionment.
The court also noted that the appeals should be granted expedition, but since they had not yet been filed, no expedition orders were made at that time.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.